Profound Medical (TSE:PRN) Stock Price Down 1.4%

Profound Medical Corp. (TSE:PRN - Get Free Report)'s stock price fell 1.4% on Friday . The company traded as low as C$10.89 and last traded at C$10.98. 4,740 shares traded hands during trading, a decline of 10% from the average session volume of 5,280 shares. The stock had previously closed at C$11.14.

Profound Medical Stock Down 1.4 %

The stock has a market capitalization of C$268.24 million, a P/E ratio of -6.00 and a beta of 0.86. The company has a debt-to-equity ratio of 25.47, a current ratio of 6.58 and a quick ratio of 14.98. The stock's fifty day moving average is C$11.41 and its two-hundred day moving average is C$12.03.

Profound Medical (TSE:PRN - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported C($0.57) earnings per share for the quarter, missing analysts' consensus estimates of C($0.38) by C($0.19). The company had revenue of C$2.74 million for the quarter, compared to analysts' expectations of C$2.56 million. As a group, research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.